TECENTRIQ®

EXPANDING FROM METASTATIC TO ADJUVANT LUNG CANCER WHERE "THE GOAL IS CURE"

2L mNSCLC

OAK Trial

Demonstrated benefit in PD-L1 all comers mOS: **13.8** months (HR 0.74)[1]

1L ES-SCLC

IMpower133

First CIT combo approved for 1L ES-SCLC mOS: **12.3** months (HR 0.70)[2]

1L mNSCLC

IMpower150

First CIT 4 drug combo to show OS advantage in EGFR TKI progressed and liver mets patients mOS: **19.5** months (HR 0.80)[3]

IMpower130

For Nsq 1L mNSCLC patients mOS: **18.6** months (HR 0.79)[4]

IMpower110

For high PD-L1 (>50%) mOS: **20.2** months (HR 0.59)[5]

TECENTRIQ® atezolizumab

NOW APPROVED in India

IN ADJUVANT NSCLC

The first and only **Immunotherapy** in resectable NSCLC

34% reduction in risk of recurrence or death vs BSC in PD-L1+ resected stage II-IIIA NSCLC patients[6]

IMpower010

M-IN-00002841 | This input is not valid after 19/6/2024 or any update

Marketed in India by:
Roche Products (India) Pvt. Ltd.
146-B, 166 A, Unit No. 7, 8, 9, 8th Floor, R City Office, R City Mall, Lal Bahadur Shastri Marg,
Ghatkopar, Mumbai - 400 086
Maharashtra; Tel No. +91 22 50457300; Fax No. +91 22 50457301

Disclaimer:
* = Registered Trade Mark F. Hoffmann - La Roche Limited, Basel, Switzerland.
For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only.
Full prescribing information available on request.
For scientific information on Roche Medicinal Product please write to india.medinfo@roche.com
For all Adverse Events/Special Situation Reports with Roche Medicinal Product please report the same to india.drugsafety@roche.com within one business day/24 hours.

Reference :
1. J Thorac Oncol. 2018 Aug;13(8):1156-1170.
2. N Engl J Med. 2018 Dec 6;379(23):2220-2229
3. J Thorac Oncol 2021 Jul 24;S1556-0864(21)02322-4
4. Lancet Oncol. 2019 Jul;20(7):924-937
5. N Engl J Med 2020 Oct 1;383(14):1328-1339
6. Felip E et al, Lancet, 2021;398:1344-1357

mNSCLC Metastatic non-small cell lung cancer
1/2L First/Second Line
Nsq Non Squamous
PD-L1 programmed death ligand 1
mOS Median overall survival
HR Hazard ratio
CIT Cancer immunotherapy
EGFR Epidermal growth factor receptor
TKI Tyrosine kinase inhibitor
ES-SCLC Extended Stage- Small cell lung cancer
DFS Disease Free Survival

http://bit.ly/Roche_Tecentriq_PI

Please use the QR code/click on the link for the latest Prescribing Information (PI). For the use only of a Registered Medical Practitioner or a Hospital or a Laboratory.